From Yahoo Finance: 2025-05-11 11:15:00

Axsome Therapeutics is gaining momentum with a treatment for major depressive disorder. Revenue surged by 62% to $121.5 million, driven by its blockbuster drug Auvelity. Axsome also announced approval for its migraine treatment, Symbravo, with potential peak sales of $341 million by 2035.

Iovance Biotherapeutics is leading in addressing solid tumors with tumor-infiltrating lymphocyte (TIL) therapies. Amtagvi, approved for advanced melanoma, generated sales of $164 million in 2024. The company is evaluating Amtagvi for cervical cancer and non-small cell lung cancer, with phase 2 trials targeting endometrial cancer and head and neck squamous cell carcinoma.

Viking Therapeutics is making waves in the anti-obesity market with promising results for VK2735. The company is developing an oral version of VK2735 and has other innovative pipeline programs. Despite being unprofitable, Viking’s progress in weight management and other areas shows significant potential for future growth.



Read more at Yahoo Finance: 3 Monster Stocks in the Making